Biocytogen (2315.HK): Rapid growth in animal models and pharmacology efficacy; Thousand Mouse Ten Thousand Antibody program continues to advance.

Company Announcement: In 2025, the company achieved operating revenue of 1.379 billion yuan, representing a year-on-year increase of 40.63%. The net profit attributable to shareholders was 173 million yuan, reflecting a year-on-year surge of 416.37%. The net profit attributable to shareholders after deducting non-recurring items was 116 million yuan.

Western SecuritiesMay 12 17:46

Stock Movement | Baiao Sai Tu-B (02315) surged over 6% in the afternoon session after the company announced plans to invest 1.6 billion yuan in the Nantong Haimen Phase IV engineering and construction project.

Biocytogen-B (02315) surged over 6% in the afternoon trading session. As of the latest update, it rose by 6.2%, closing at HKD 54.8, with a turnover of HKD 48.4577 million.

Zhitong FinanceMay 12 13:41

Biocytogen Pharmaceuticals-B (02315.HK) received an increase of 63,500 H-shares by Fullgoal Fund Management Co., Ltd., valued at approximately 3.1519 million Hong Kong dollars.

According to a report on May 11, based on the document disclosed by the Hong Kong Stock Exchange on May 11, Fuguo Fund Management Co., Ltd. increased its holdings of 63,500 H-shares of $Baiao Sai Tu-B (02315.HK)$ at an average price of 49.6365 Hong Kong dollars per share on May 7, with a total value of approximately 3.1519 million Hong Kong dollars. After the increase in holdings, Fuguo Fund Management Co., Ltd.'s latest number of shares held is 5.545 million shares, and the proportion of long positions has increased from 4.95% to 5.01%. Source of image: Disclosure of equity interests by the Stock Exchange. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more shares) are required to disclose...

Futu NewsMay 11 17:12

Baiao Sai Tu (688796): Dual Drivers of Model Animals and Antibody Licensing Propel Continuous Profitability Growth

The core perspective indicates that the company's revenue grew by 40.63% year-over-year in 2025, achieving simultaneous improvements in income, profit, and cash flow. In the first quarter of 2026, driven by model organisms, pharmacology and efficacy services, and milestone-based income, the company continued its high growth trajectory, generating a revenue of 4.

CSC Financial Co., Ltd.May 9 18:22

Biocytogen Clarifies AGM Resolution on RMB1.5 Billion Credit Facilities and Guarantees

TipRanksMay 7 22:40

Biocytogen (688796): Robust Growth in Animal Model and Preclinical Services, Antibody Development Platform Accelerates Value Realization

Key investment highlights: In 2025, the company achieved revenue of 1.379 billion yuan, representing a year-on-year increase of over 40%; net profit attributable to shareholders reached 173 million yuan, marking a year-on-year surge of 416.37%; and non-recurring net profit amounted to 116 million yuan, reflecting a year-on-year growth of 405 times.

China Post SecuritiesMay 7 00:00